NASDAQ:PTGX - Protagonist Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $7.88 +0.35 (+4.65 %) (As of 07/18/2018 04:34 AM ET)Previous Close$7.53Today's Range$7.51 - $7.9652-Week Range$5.50 - $23.97Volume92,278 shsAverage Volume252,490 shsMarket Capitalization$157.97 millionP/E Ratio-3.77Dividend YieldN/ABeta3.32 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California. Receive PTGX News and Ratings via Email Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:PTGX CUSIPN/A Webwww.protagonist-inc.com Phone510-474-0170 Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio4.19 Price-To-Earnings Trailing P/E Ratio-3.77 Forward P/E Ratio-8.04 P/E GrowthN/A Sales & Book Value Annual Sales$20.06 million Price / Sales8.33 Cash FlowN/A Price / CashN/A Book Value$5.89 per share Price / Book1.34 Profitability EPS (Most Recent Fiscal Year)($2.09) Net Income$-36,950,000.00 Net MarginsN/A Return on Equity-34.47% Return on Assets-24.72% Miscellaneous Employees55 Outstanding Shares21,200,000Market Cap$157.97 Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions What is Protagonist Therapeutics' stock symbol? Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX." How were Protagonist Therapeutics' earnings last quarter? Protagonist Therapeutics Inc (NASDAQ:PTGX) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.07. The business had revenue of $10.78 million for the quarter, compared to analyst estimates of $10.70 million. View Protagonist Therapeutics' Earnings History. When is Protagonist Therapeutics' next earnings date? Protagonist Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Protagonist Therapeutics. What price target have analysts set for PTGX? 4 brokers have issued 12 month target prices for Protagonist Therapeutics' stock. Their predictions range from $13.00 to $36.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $24.75 in the next year. This suggests a possible upside of 214.1% from the stock's current price. View Analyst Ratings for Protagonist Therapeutics. What is the consensus analysts' recommendation for Protagonist Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of Protagonist Therapeutics' key competitors? Some companies that are related to Protagonist Therapeutics include Geron (GERN), Evolus (EOLS), Progenics Pharmaceuticals (PGNX), Innovate Biopharmaceuticals (INNT), Five Prime Therapeutics (FPRX), Obseva (OBSV), Prothena (PRTA), Theratechnologies (THERF), CannTrust (CNTTF), Beyondspring (BYSI), Merus (MRUS), Akebia Therapeutics (AKBA), Insys Therapeutics (INSY), Arcus Biosciences (RCUS) and Aduro BioTech (ADRO). Who are Protagonist Therapeutics' key executives? Protagonist Therapeutics' management team includes the folowing people: Dr. Dinesh V. Patel, CEO, Pres, Sec. & Director (Age 61)Dr. Richard S. Shames M.D., Chief Medical Officer (Age 58)Dr. David Y. Liu Ph.D., Chief Scientific Officer and Head of R&D (Age 68)Mr. Thomas P. O'Neil, CFO & Principal Accounting Officer (Age 53)Dr. Mark Smythe Ph.D., VP of Technology & Alliances (Age 53) When did Protagonist Therapeutics IPO? (PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO. Has Protagonist Therapeutics been receiving favorable news coverage? Headlines about PTGX stock have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Protagonist Therapeutics earned a news impact score of 0.07 on Accern's scale. They also gave headlines about the company an impact score of 46.77 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. Who are Protagonist Therapeutics' major shareholders? Protagonist Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Franklin Street Advisors Inc. NC (0.13%). Company insiders that own Protagonist Therapeutics stock include Armen Shanafelt, Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics. Which major investors are selling Protagonist Therapeutics stock? PTGX stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Insider Buying and Selling for Protagonist Therapeutics. How do I buy shares of Protagonist Therapeutics? Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protagonist Therapeutics' stock price today? One share of PTGX stock can currently be purchased for approximately $7.88. How big of a company is Protagonist Therapeutics? Protagonist Therapeutics has a market capitalization of $157.97 million and generates $20.06 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Protagonist Therapeutics employs 55 workers across the globe. How can I contact Protagonist Therapeutics? Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560-1160. The company can be reached via phone at 510-474-0170 or via email at [email protected] MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 108 (Vote Outperform)Underperform Votes: 152 (Vote Underperform)Total Votes: 260MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?